BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34910538)

  • 21. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
    Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
    Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
    Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
    Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
    Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
    Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 28. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.
    Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD
    Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.
    Li CQ; Zheng X; Guo HL; Cheng MQ; Huang Y; Xie XY; Lu MD; Kuang M; Wang W; Chen LD
    BMC Med Imaging; 2022 Mar; 22(1):36. PubMed ID: 35241004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
    Makoyeva A; Kim TK; Jang HJ; Medellin A; Wilson SR
    Radiol Imaging Cancer; 2020 Mar; 2(2):e190014. PubMed ID: 33778701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
    Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
    Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nodules Identified on Surveillance Ultrasound for HCC: CEUS or MRI as the Initial Test?
    Hu J; Burrowes DP; Caine BA; Gibson N; Bhayana D; Medellin A; Burak KW; Wilson SR
    J Ultrasound Med; 2023 Jun; 42(6):1181-1190. PubMed ID: 36807925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2017)- a valuable tool for the noninvasive diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
    Ghiuchici AM; Dănilă M; Popescu A; Șirli R; Moga T; Topan M; Bende F; Sporea I
    Med Ultrason; 2021 Nov; 23(4):383-389. PubMed ID: 33793696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feeding artery: a valuable feature for differentiation of regenerative nodule, dysplastic nodules and small hepatocellular carcinoma in CEUS LI-RADS.
    Wu J; Zhao Q; Wang Y; Xiao F; Cai W; Liu S; Du Z; Yu X; Liu F; Yu J; Liang P
    Eur Radiol; 2024 Feb; 34(2):745-754. PubMed ID: 37589899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
    Huang Z; Zhou P; Li S; Li K
    Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Contrast-Enhanced Ultrasound versus Contrast-Enhanced Magnetic Resonance Imaging for the Diagnosis of Focal Liver Lesions Using the Liver Imaging Reporting and Data System.
    Wang JY; Feng SY; Yi AJ; Zhu D; Xu JW; Li J; Cui XW; Dietrich CF
    Ultrasound Med Biol; 2020 May; 46(5):1216-1223. PubMed ID: 32115307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.